{"id":"NCT00923091","sponsor":"Daiichi Sankyo","briefTitle":"Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension","officialTitle":"Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination in Subjects With Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2011-01","completion":"2011-03","firstPosted":"2009-06-18","resultsPosted":"2012-04-06","lastUpdate":"2019-01-10"},"enrollment":2689,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Essential Hypertension"],"interventions":[{"type":"DRUG","name":"olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo","otherNames":["Azor"]},{"type":"DRUG","name":"Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo","otherNames":["Azor"]},{"type":"DRUG","name":"olmesartan medoxomil + amlodipine + hydroclororthiazide","otherNames":["Azor","Norvasc"]},{"type":"DRUG","name":"olmesartan medoxomil + amlodipine + hydroclororthiazide","otherNames":["Azor"]},{"type":"DRUG","name":"olmesartan medoxomil + amlodipine + hydroclororthiazide","otherNames":["Azor"]},{"type":"DRUG","name":"olmesartan medoxomil + amlodipine","otherNames":["Azor"]},{"type":"DRUG","name":"olmesartan medoxomil + amlodipine","otherNames":[]},{"type":"DRUG","name":"olmesartan medoxomil + amlodipine","otherNames":["Azor"]}],"arms":[{"label":"olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5mg","type":"EXPERIMENTAL"},{"label":"olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5mg","type":"EXPERIMENTAL"},{"label":"olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/25mg","type":"EXPERIMENTAL"},{"label":"olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/12.5mg","type":"EXPERIMENTAL"},{"label":"olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/25mg","type":"EXPERIMENTAL"},{"label":"olmesartan/amlodipine 20mg/5mg","type":"EXPERIMENTAL"},{"label":"olmesartan/amlodipine 40mg/5mg","type":"EXPERIMENTAL"},{"label":"olmesartan/amlodipine 40mg/10mg","type":"EXPERIMENTAL"}],"summary":"This study is to determine the change in blood pressure from the administration of Olmesartan/Amlodipine/Hydrochlorothiazide triple combinations compared to dual combinations with Olmesartan/Amlodipine.","primaryOutcome":{"measure":"Change in Seated Diastolic Blood Pressure (SeDBP).","timeFrame":"Baseline to week 10","effectByArm":[{"arm":"Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg","deltaMin":-22.5,"sd":0.48},{"arm":"Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg","deltaMin":-22.5,"sd":0.48},{"arm":"Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg","deltaMin":-23,"sd":0.48},{"arm":"Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg","deltaMin":-23.9,"sd":0.47},{"arm":"Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg","deltaMin":-23.8,"sd":0.48},{"arm":"Olmesartan/Amlodipine 20mg/5mg","deltaMin":-20.5,"sd":0.47},{"arm":"Olmesartan/Amlodipine 40mg/5mg","deltaMin":-21.2,"sd":0.48},{"arm":"Olmesartan/Amlodipine 40mg/10mg","deltaMin":-22.1,"sd":0.48}],"pValues":[{"comp":"OG000 vs OG005","p":"0.0071"},{"comp":"OG001 vs OG006","p":"0.0323"},{"comp":"OG002 vs OG006","p":"0.0080"},{"comp":"OG003 vs OG007","p":"0.0071"},{"comp":"OG004 vs OG007","p":"0.0107"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":28},"locations":{"siteCount":133,"countries":["Belgium","Bulgaria","Czechia","Denmark","Germany","Hungary","Italy","Latvia","Netherlands","Poland","Romania","Russia","Slovakia","Spain","Ukraine"]},"refs":{"pmids":["25879524","24760656","22909147"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":55,"n":329},"commonTop":["Oedema peripheral","Headache","Nasopharyngitis","Dyslipidaemia"]}}